Edition:
United Kingdom

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

995.00GBp
18 Jan 2018
Change (% chg)

-27.50 (-2.69%)
Prev Close
1,022.50
Open
1,023.00
Day's High
1,023.00
Day's Low
989.80
Volume
494,673
Avg. Vol
1,041,553
52-wk High
2,346.00
52-wk Low
906.50

Chart for

About

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products... (more)

Overall

Beta: 1.34
Market Cap(Mil.): £2,897.33
Shares Outstanding(Mil.): 240.65
Dividend: 8.50
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

Hikma wins right to market Roche drug copy in Middle East and North Africa

Hikma Pharmaceuticals Plc has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday.

19 Dec 2017

Hikma wins right to market Roche drug copy in Middle East and North Africa

Dec 19 Hikma Pharmaceuticals Plc has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday.

19 Dec 2017

BRIEF-Hikma Pharmaceuticals ‍Reaches Licensing Agreement With Celltrion

* ‍REACHES LICENSING AGREEMENT WITH CELLTRION FOR THIRD BIOSIMILAR PRODUCT IN MIDDLE EAST AND NORTH AFRICA​

19 Dec 2017

BRIEF-Hikma Says Hikma Ventures Has Participated In Financing For Prognos​

* ‍VENTURE CAPITAL ARM, HIKMA VENTURES HAS PARTICIPATED IN A $20.5 MILLION SERIES C ROUND OF FINANCING FOR PROGNOS​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

30 Nov 2017

BRIEF-Hikma Pharmaceuticals ‍invests in biosensor tech firm Biolinq​

* HIKMA PHARMACEUTICALS PLC - ‍INVESTED IN BIOLINQ IN COLLABORATION WITH M VENTURES WHICH LED $10 MILLION SERIES A ROUND OF FINANCING​ Source text for Eikon: Further company coverage:

27 Nov 2017

BRIEF-Hikma Pharmaceuticals acquires six products from Boehringer Ingelheim GmbH

* ‍HIKMA ACQUIRES PRODUCTS IN EUROPE FROM BOEHRINGER INGELHEIM​

14 Nov 2017

Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

Hikma Pharmaceuticals Plc is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

09 Nov 2017

UPDATE 1-Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

Nov 9 Hikma Pharmaceuticals Plc is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

09 Nov 2017

Drugmaker Hikma cuts generics sales forecast a third time

Nov 9 Hikma Pharmaceuticals Plc on Thursday lowered 2017 revenue guidance for its generics business for a third time.

09 Nov 2017

BRIEF-Hikma Pharmaceuticals says ‍continue to expect FY revenue around $2.0 bln​

* ‍CONTINUE TO EXPECT FULL YEAR REVENUE TO BE AROUND $2.0 BILLION IN CONSTANT CURRENCY IN 2017​

09 Nov 2017

Earnings vs. Estimates